Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: firstname.lastname@example.org. Type 508 Accommodation and the title of the report in the subject line of e-mail.
Recommended Adult Immunization Schedule --- United States, 2009
The Recommended Adult Immunization Schedule has been approved by the Advisory Committee on
Immunization Practices, the American Academy of Family Physicians, the American College of Obstetricians and Gynecologists, and
the American College of Physicians.
Suggested citation: Centers for Disease Control and Prevention. Recommended adult immunization
schedule---United States, 2009. MMWR 2008;57(53).
The Advisory Committee on Immunization Practices (ACIP) annually reviews the recommended Adult
Immunization Schedule to ensure that the schedule reflects current recommendations for the licensed vaccines. In October 2008,
ACIP approved the Adult Immunization Schedule for 2009. No new vaccines were added to the schedule; however,
several indications were added to the pneumococcal polysaccharide vaccine footnote, clarifications were made to the footnotes
for human papillomavirus, varicella, and meningococcal vaccines, and schedule information was added to the hepatitis A
and hepatitis B vaccine footnotes.
To make the figures easier to understand, several formatting changes were implemented to both the age
group--based schedule and the medical and other indications schedule. The changes include 1) increasing the number of age groups;
2) deleting the hatched yellow bar for tetanus, diphtheria, pertussis (Td/Tdap) vaccine while adding explanatory text to the
Td/Tdap bar; 3) simplifying the figures by removing schedule text from the vaccine bars; 4) revising the order of the vaccines
to more appropriately group the vaccines, and 5) adding a legend box to clarify the meaning of blank spaces in the table.
Footnote (Figures 1 and 2)
The human papillomavirus (HPV) footnote (#2) has language added to indicate that health-care personnel are not
at increased risk because of occupational exposure, but they should be vaccinated consistent with
age-based recommendations. Also, text has been added to indicate that vaccination with HPV may begin at age 9 years.
The varicella footnote (#3) has language added to clarify that adults who previously received only 1 dose of vaccine
should receive a second dose.
Asthma and cigarette smoking have been added as indications for pneumococcal polysaccharide vaccination (#7). Also,
text has been added to clarify vaccine use in Alaska Natives and American Indians.
The Hepatitis A footnote (#9) has additional schedule information for the 4-dose combined hepatitis A/hepatitis B vaccine.
The Hepatitis B footnote (#10) has additional schedule information for the 4-dose combined hepatitis A/hepatitis
B vaccine, and a clarification of schedule information for special formulation indications has been added.
The meningococcal vaccine footnote (#11) clarifies that the revaccination interval is 5 years.
FIGURE 1. Recommended adult immunization schedule by vaccine and age group --- United Sates, 2009
NOTE: The above recommendations must be read along with the footnotes on pages Q2--Q4 of this schedule.
FIGURE 2. Vaccines that might be indicated for adults based on medical and other indications --- United States, 2009
NOTE: The above recommendations must be read along with the footnotes on pages Q2--Q4 of this schedule.
1. Tetanus, diphtheria, and acellular pertussis (Td/Tdap) vaccination
Tdap should replace a single dose of Td for adults aged 19 through 64 years who have not received a dose of
Adults with uncertain or incomplete history of primary vaccination series with tetanus and diphtheria
toxoid--containing vaccines should begin or complete a primary vaccination series. A primary series for adults is 3 doses of tetanus and
diphtheria toxoid--containing vaccines; administer the first 2 doses at least 4 weeks apart and the third dose 6--12 months after
the second. However, Tdap can substitute for any one of the doses of Td in the 3-dose primary series. The booster dose of
tetanus and diphtheria toxoid--containing vaccine should be administered to adults who have completed a primary series and if
the last vaccination was received 10 or more years previously. Tdap or Td vaccine may be used, as indicated.
If a woman is pregnant and received the last Td vaccination 10 or more years previously, administer Td during the second
or third trimester. If the woman received the last Td vaccination less than 10 years previously, administer Tdap during
the immediate postpartum period. A dose of Tdap is recommended for postpartum women, close contacts of infants aged
less than 12 months, and all health-care personnel with direct patient contact if they have not previously received Tdap.
An interval as short as 2 years from the last Td is suggested; shorter intervals can be used. Td may be deferred during
pregnancy and Tdap substituted in the immediate postpartum period, or Tdap may be administered instead of Td to a pregnant
woman after an informed discussion with the woman.
Consult the ACIP statement for recommendations for administering Td as prophylaxis in wound management.
2. Human papillomavirus (HPV) vaccination
HPV vaccination is recommended for all females aged 11 through 26 years (and may begin at age 9 years) who have
not completed the vaccine series. History of genital warts, abnormal Papanicolaou test, or positive HPV DNA test is not
evidence of prior infection with all vaccine HPV types; HPV vaccination is recommended for persons with such histories.
Ideally, vaccine should be administered before potential exposure to HPV through sexual activity; however, females who
are sexually active should still be vaccinated consistent with age-based recommendations. Sexually active females who have
not been infected with any of the four HPV vaccine types receive the full benefit of the vaccination. Vaccination is less
beneficial for females who have already been infected with one or more of the HPV vaccine types.
A complete series consists of 3 doses. The second dose should be administered 2 months after the first dose; the third
dose should be administered 6 months after the first dose.
HPV vaccination is not specifically recommended for females with the medical indications described in Figure 2,
"Vaccines that might be indicated for adults based on medical and other indications." Because HPV vaccine is not a live-virus vaccine,
it may be administered to persons with the medical indications described in Figure 2. However, the immune response
and vaccine efficacy might be less for persons with the medical indications described in Figure 2 than in persons who do not
have the medical indications described or who are immunocompetent. Health-care personnel are not at increased risk because
of occupational exposure, and should be vaccinated consistent with age-based recommendations.
3. Varicella vaccination
All adults without evidence of immunity to varicella should receive 2 doses of single-antigen varicella vaccine if
not previously vaccinated or the second dose if they have received only one dose, unless they have a medical
contraindication. Special consideration should be given to those who 1) have close contact with persons at high risk for severe disease
(e.g., health-care personnel and family contacts of persons with immunocompromising conditions) or 2) are at high risk
for exposure or transmission (e.g., teachers; child care employees; residents and staff members of institutional settings,
including correctional institutions; college students; military personnel; adolescents and adults living in households with
children; nonpregnant women of childbearing age; and international travelers).
Evidence of immunity to varicella in adults includes any of the following: 1) documentation of 2 doses of varicella vaccine
at least 4 weeks apart; 2) U.S.-born before 1980 (although for health-care personnel and pregnant women, birth before
1980 should not be considered evidence of immunity); 3) history of varicella based on diagnosis or verification of varicella by
a health-care provider (for a patient reporting a history of or presenting with an atypical case, a mild case, or both,
health-care providers should seek either an epidemiologic link to a typical varicella case or to a laboratory-confirmed case or evidence
laboratory confirmation, if it was performed at the time of acute disease); 4) history of herpes zoster based on
health-care provider diagnosis or verification of herpes zoster by a health-care provider; or 5) laboratory evidence of immunity
or laboratory confirmation of disease.
Pregnant women should be assessed for evidence of varicella immunity. Women who do not have evidence of
immunity should receive the first dose of varicella vaccine upon completion or termination of pregnancy and before discharge from
the health-care facility. The second dose should be administered 4--8 weeks after the first dose.
4. Herpes zoster vaccination
A single dose of zoster vaccine is recommended for adults aged 60 years and older regardless of whether they report a
prior episode of herpes zoster. Persons with chronic medical conditions may be vaccinated unless their condition constitutes
5. Measles, mumps, rubella (MMR) vaccination
Measles component: Adults born before 1957 generally are considered immune to measles. Adults born during or after
1957 should receive 1 or more doses of MMR unless they have a medical contraindication, documentation of 1 or more
doses, history of measles based on health-care provider diagnosis, or laboratory evidence of immunity.
A second dose of MMR is recommended for adults who 1) have been recently exposed to measles or are in an
outbreak setting; 2) have been vaccinated previously with killed measles vaccine; 3) have been vaccinated with an unknown type
of measles vaccine during 1963--1967; 4) are students in postsecondary educational institutions; 5) work in a health-care
facility; or 6) plan to travel internationally.
Mumps component: Adults born before 1957 generally are considered immune to mumps. Adults born during or
after 1957 should receive 1 dose of MMR unless they have a medical contraindication, history of mumps based on
health-care provider diagnosis, or laboratory evidence of immunity.
A second dose of MMR is recommended for adults who 1) live in a community experiencing a mumps outbreak and are
in an affected age group; 2) are students in postsecondary educational institutions; 3) work in a health-care facility; or 4) plan
to travel internationally. For unvaccinated health-care personnel born before 1957 who do not have other evidence of
mumps immunity, administering 1 dose on a routine basis should be considered and administering a second dose during an
outbreak should be strongly considered.
Rubella component: 1 dose of MMR vaccine is recommended for women whose rubella vaccination history is unreliable
or who lack laboratory evidence of immunity. For women of childbearing age, regardless of birth year, rubella immunity
should be determined and women should be counseled regarding congenital rubella syndrome. Women who do not have evidence
of immunity should receive MMR vaccine upon completion or termination of pregnancy and before discharge from the
6. Influenza vaccination
Medical indications: Chronic disorders of the cardiovascular or pulmonary systems, including asthma; chronic
metabolic diseases, including diabetes mellitus, renal or hepatic dysfunction, hemoglobinopathies, or immunocompromising
conditions (including immunocompromising conditions caused by medications or human immunodeficiency virus [HIV]);
any condition that compromises respiratory function or the handling of respiratory secretions or that can increase the risk
of aspiration (e.g., cognitive dysfunction, spinal cord injury, or seizure disorder or other neuromuscular disorder); and
pregnancy during the influenza season. No data exist on the risk for severe or complicated influenza disease among persons with
asplenia; however, influenza is a risk factor for secondary bacterial infections that can cause severe disease among persons with asplenia.
Occupational indications: All health-care personnel, including those employed by long-term care and
assisted-living facilities, and caregivers of children less than 5 years old.
Other indications: Residents of nursing homes and other long-term care and assisted-living facilities; persons likely
to transmit influenza to persons at high risk (e.g., in-home household contacts and caregivers of children aged less than 5
years old, persons 65 years old and older and persons of all ages with high-risk condition[s]); and anyone who would like
to decrease their risk of getting influenza. Healthy, nonpregnant adults aged less than 50 years without high-risk
medical conditions who are not contacts of severely immunocompromised persons in special care units can receive either
intranasally administered live, attenuated influenza vaccine
(FluMist®) or inactivated vaccine. Other persons should receive the
7. Pneumococcal polysaccharide (PPSV) vaccination
Medical indications: Chronic lung disease (including asthma); chronic cardiovascular diseases; diabetes mellitus;
chronic liver diseases, cirrhosis; chronic alcoholism, chronic renal failure or nephrotic syndrome; functional or anatomic asplenia
(e.g., sickle cell disease or splenectomy [if elective splenectomy is planned, vaccinate at least 2 weeks before
surgery]); immunocompromising conditions; and cochlear implants and cerebrospinal fluid leaks. Vaccinate as close to HIV diagnosis
Other indications: Residents of nursing homes or other long-term care facilities and persons who smoke cigarettes.
Routine use of PPSV is not recommended for Alaska Native or American Indian persons younger than 65 years unless they
have underlying medical conditions that are PPSV indications. However, public health authorities may consider
recommending PPSV for Alaska Natives and American Indians aged 50 through 64 years who are living in areas in which the risk of
invasive pneumococcal disease is increased.
8. Revaccination with PPSV
One-time revaccination after 5 years is recommended for persons with chronic renal failure or nephrotic
syndrome; functional or anatomic asplenia (e.g., sickle cell disease or splenectomy); and for persons with
immunocompromising conditions. For persons aged 65 years and older, one-time revaccination if they were vaccinated 5 or more years previously
and were aged less than 65 years at the time of primary vaccination.
9. Hepatitis A vaccination
Medical indications: Persons with chronic liver disease and persons who receive clotting factor concentrates.
Behavioral indications: Men who have sex with men and persons who use illegal drugs.
Occupational indications: Persons working with hepatitis A virus (HAV)--infected primates or with HAV in a
research laboratory setting.
Other indications: Persons traveling to or working in countries that have high or intermediate endemicity of hepatitis A
(a list of countries is available at
http://wwwn.cdc.gov/travel/contentdiseases.aspx) and any person seeking protection from HAV infection.
Single-antigen vaccine formulations should be administered in a 2-dose schedule at either 0 and 6--12 months
(Havrix®), or 0 and 6--18 months
(Vaqta®). If the combined hepatitis A and hepatitis B vaccine
(Twinrix®) is used, administer 3 doses at
0, 1, and 6 months; alternatively, a 4-dose schedule, administered on days 0, 7, and 21 to 30 followed by a booster dose
at month 12 may be used.
10. Hepatitis B vaccination
Medical indications: Persons with end-stage renal disease, including patients receiving hemodialysis; persons with
HIV infection; and persons with chronic liver disease.
Occupational indications: Health-care personnel and public-safety workers who are exposed to blood or other
potentially infectious body fluids.
Behavioral indications: Sexually active persons who are not in a long-term, mutually monogamous relationship (e.g.,
persons with more than 1 sex partner during the previous 6 months); persons seeking evaluation or treatment for a
sexually transmitted disease (STD);current or recent injection-drug users; and men who have sex with men.
Other indications: Household contacts and sex partners of persons with chronic hepatitis B virus (HBV) infection;
clients and staff members of institutions for persons with developmental disabilities; international travelers to countries with high
or intermediate prevalence of chronic HBV infection (a list of countries is available at
http://wwwn.cdc.gov/travel/contentdiseases.aspx); and any adult seeking protection from HBV infection.
Hepatitis B vaccination is recommended for all adults in the following settings: STD treatment facilities; HIV testing
and treatment facilities; facilities providing drug-abuse treatment and prevention services; health-care settings targeting services
to injection-drug users or men who have sex with men; correctional facilities; end-stage renal disease programs and facilities
for chronic hemodialysis patients; and institutions and nonresidential daycare facilities for persons with developmental disabilities.
If the combined hepatitis A and hepatitis B vaccine
(Twinrix®) is used, administer 3 doses at 0, 1, and 6
months; alternatively, a 4-dose schedule, administered on days 0, 7, and 21 to 30 followed by a booster dose at month 12 may be used.
Special formulation indications: For adult patients receiving hemodialysis or with other immunocompromising
conditions, 1 dose of 40 µg/mL (Recombivax
HB®) administered on a 3-dose schedule or 2 doses of 20
administered simultaneously on a 4-dose schedule at 0,1, 2 and 6 months.
11. Meningococcal vaccination
Medical indications: Adults with anatomic or functional asplenia, or terminal complement component deficiencies.
Other indications: First-year college students living in dormitories; microbiologists routinely exposed to isolates of
Neisseria meningitidis; military recruits; and persons who travel to or live in countries in which meningococcal disease is
hyperendemic or epidemic (e.g., the "meningitis belt" of sub-Saharan Africa during the dry season [December--June]), particularly if
their contact with local populations will be prolonged. Vaccination is required by the government of Saudi Arabia for all travelers
to Mecca during the annual Hajj.
Meningococcal conjugate vaccine (MCV) is preferred for adults with any of the preceding indications who are aged 55
years or younger, although meningococcal polysaccharide vaccine (MPSV) is an acceptable alternative. Revaccination with
MCV after 5 years might be indicated for adults previously vaccinated with MPSV who remain at increased risk for infection
(e.g., persons residing in areas in which disease is epidemic).
12. Selected conditions for which Haemophilus influenzae type b (Hib) vaccine may be used
Hib vaccine generally is not recommended for persons aged 5 years and older. No efficacy data are available on which
to base a recommendation concerning use of Hib vaccine for older children and adults. However, studies suggest
good immunogenicity in patients who have sickle cell disease, leukemia, or HIV infection or who have had a
splenectomy; administering 1 dose of vaccine to these patients is not contraindicated.
13. Immunocompromising conditions
Inactivated vaccines generally are acceptable (e.g., pneumococcal, meningococcal, and influenza [trivalent
inactivated influenza vaccine]) and live vaccines generally are avoided in persons with immune deficiencies or
immunocompromising conditions. Information on specific conditions is available at
These schedules indicate the recommended age groups and medical indications for which administration of
currently licensed vaccines is commonly indicated for adults ages 19 years and older, as of January 1, 2009. Licensed
combination vaccines may be used whenever any components of the combination are indicated and when the vaccine's other
components are not contraindicated. For detailed recommendations on all vaccines, including those used primarily for travelers or that
are issued during the year, consult the manufacturers' package inserts and the complete statements from the Advisory
Committee on Immunization Practices (http://www.cdc.gov/vaccines/pubs/acip-list.htm).
Report all clinically significant postvaccination reactions to the Vaccine Adverse Event Reporting System
(VAERS). Reporting forms and instructions on filing a VAERS report are available at
http://www.vaers.hhs.gov or by telephone,
Information on how to file a Vaccine Injury Compensation Program claim is available at
http://www.hrsa.gov/vaccinecompensation or by telephone, 800-338-2382. To file a claim for vaccine injury, contact the U.S. Court of
Federal Claims, 717 Madison Place, N.W., Washington, D.C. 20005; telephone, 202-357-6400.
Additional information about the vaccines in this schedule, extent of available data, and contraindications for vaccination
is also available at http://www.cdc.gov/vaccines or from the CDC-INFO Contact Center at 800-CDC-INFO
(800-232-4636) in English and Spanish, 24 hours a day, 7 days a week.
Use of trade names and commercial sources is for identification only and does not imply endorsement by the
U.S. Department of Health and Human Services.
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of
Health and Human Services.References to non-CDC sites on the Internet are
provided as a service to MMWR readers and do not constitute or imply
endorsement of these organizations or their programs by CDC or the U.S.
Department of Health and Human Services. CDC is not responsible for the content
of pages found at these sites. URL addresses listed in MMWR were current as of
the date of publication.
All MMWR HTML versions of articles are electronic conversions from typeset documents.
This conversion might result in character translation or format errors in the HTML version.
Users are referred to the electronic PDF version (http://www.cdc.gov/mmwr)
and/or the original MMWR paper copy for printable versions of official text, figures, and tables.
An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S.
Government Printing Office (GPO), Washington, DC 20402-9371;
telephone: (202) 512-1800. Contact GPO for current prices.
**Questions or messages regarding errors in formatting should be addressed to